EUVIMEDEUVIMED entdecken
Fallbericht

Early anti-C5 therapy in NMOSD: rationale and clinical evidence

Haruka Kido, Satoru Morimoto, Mikiaki Matsuoka

Neurological Sciences · 2026-04 · 47 (4)

DOI: 10.1007/s10072-026-08952-2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neurological Sciences, online erschienen am 14.03.2026. Verfasst von Haruka Kido und 2 weiteren Autor:innen. Beteiligte Einrichtung: St. Mary's Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaAntibodies, Monoclonal, HumanizedHumansFemaleAdultAquaporin 4

Stichwörter der Autor:innen

50% hemolytic complement activity (CH50)Acute neuroinflammationAquaporin-4 antibodies (AQP4-IgG)Autoimmune astrocytopathyComplement C5 inhibitionEculizumabNeuromyelitis optica spectrum disorder (NMOSD)RavulizumabRescue therapy

Substanzen

Aquaporin 4Antibodies, Monoclonal, Humanizedeculizumab

Autor:innen und Institutionen

  • St. Mary's Hospital, Fukuoka, Japan.
  • Keio University Regenerative Medicine Research Center, Kanagawa, Japan. satoru_morimoto@keio.jp.
  • Department of Cerebrovascular Medicine, Kyushu University, Fukuoka, Japan.

Zitieren

APA

Kido, H., Morimoto, S., & Matsuoka, M. (2026). Early anti-C5 therapy in NMOSD: rationale and clinical evidence. Neurological Sciences, 47(4). https://doi.org/10.1007/s10072-026-08952-2

Vancouver

Kido H, Morimoto S, Matsuoka M. Early anti-C5 therapy in NMOSD: rationale and clinical evidence. Neurological Sciences. 2026;47(4). doi:10.1007/s10072-026-08952-2

BibTeX
@article{Kido2026,
  author = {Kido, Haruka and Morimoto, Satoru and Matsuoka, Mikiaki},
  title = {Early anti-C5 therapy in NMOSD: rationale and clinical evidence},
  journal = {Neurological Sciences},
  year = {2026},
  volume = {47},
  number = {4},
  doi = {10.1007/s10072-026-08952-2}
}
Kostenlos starten →